Marshall Wace, LLP Tg Therapeutics, Inc. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$13.32 - $19.19 $27.3 Million - $39.4 Million
2,051,762 New
2,051,762 $36.5 Million
Q4 2023

Feb 14, 2024
BUY
$6.68 - $18.81 $6.81 Million - $19.2 Million
1,020,102 New
1,020,102 $17.4 Million
Q2 2020

Aug 13, 2020
SELL
$8.9 - $21.84 $219,269 - $538,072
-24,637 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$7.14 - $15.99 $175,908 - $393,945
24,637 New
24,637 $242,000

Others Institutions Holding TGTX

# of Institutions
345
Shares Held
87.6M
Call Options Held
2.35M
Put Options Held
1.7M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.86B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email